Low molecular weight heparin for the prevention of severe preeclampsia: where next?

29Citations
Citations of this article
55Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high-risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high-risk women for participation in future trials, and the importance of trial standardization.

Cite

CITATION STYLE

APA

McLaughlin, K., Scholten, R. R., Parker, J. D., Ferrazzi, E., & Kingdom, J. C. P. (2018, April 1). Low molecular weight heparin for the prevention of severe preeclampsia: where next? British Journal of Clinical Pharmacology. Blackwell Publishing Ltd. https://doi.org/10.1111/bcp.13483

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free